Phase III Randomized Study of Paclitaxel +/- Bevacizumab in Patients With Metastatic Breast Cancer

Summary:
A reasonable standard of care for women with metastatic breast cancer is paclitaxel, but clinical studies are underway to try and improve upon this standard. Bevacizumab is a compound which has been shown in research to cut off the blood supply to a tumor, eventually hoping to shrink tumor size. It is not yet known if chemotherapy is more effective with or without bevacizumab in treating breast cancer.

Eligibility:
The trial will be conducted in individuals with metastatic breast cancer. Eligible participants must be 18 years or older to enroll and must not have received chemotherapy, immunotherapy, or radiotherapy for at least four weeks prior to entry in the study. In addition, participants may not receive concurrent treatment with any other investigational drugs while on this protocol. Eligible participants must be disease-free of prior invasive malignancies for more than five years with the exception of basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix. Patients with a history of bleeding problems, including blood clots, are not eligible for this study.

Benefits and/or Compensation:
Participants receive free study-related medication under the supervision and care of a team of medical professionals.